13F filer · CIK 1609251
Krensavage Asset Management, LLC
NEW YORK, NY · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$263.2M
+$7.5M vs prior
Positions
18
New / sold out
0 / 2
Added / reduced
4 / 2
Turnover
7.9%
buys $20.4M · sells $24.7M
Top-10 weight
89.4%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | ABBOTT LABORATORIES | +195,000 | +3900.0% | +$17.7M |
| Added | EMBECTA CORP | +400,000 | +54.4% | +$1.3M |
| Added | REGENERON PHARMACEUTICALS | +2,000 | +50.0% | +$1.2M |
| Added | ARDELYX INC | +34,523 | +6.9% | +$176.1K |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | INDIVIOR PHARMACEUTICALS INC | -339,532 | -100.0% | $-10.3M |
| Reduced | UNITED THERAPEUTICS CORP | -15,000 | -17.8% | $-8.1M |
| Sold out | ALKERMES PLC | -107,822 | -100.0% | $-3.8M |
| Reduced | EXELIXIS INC | -45,000 | -10.8% | $-2.4M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ENANTA PHARMACEUTICALS INCCOM | 2,866,138 | $41.8M | 15.88% |
| 2 | JAZZ PHARMACEUTICALS PLCCOM | 167,816 | $40.4M | 15.36% |
| 3 | UNITED THERAPEUTICS CORPCOM | 69,282 | $37.5M | 14.26% |
| 4 | BIOMARIN PHARMACEUTICAL INCCOM | 524,786 | $30.0M | 11.41% |
| 5 | EXELIXIS INCCOM | 370,693 | $20.2M | 7.66% |
| 6 | ABBOTT LABORATORIESCOM | 200,000 | $18.1M | 6.89% |
| 7 | SANOFI-ADRCOM | 323,946 | $13.8M | 5.25% |
| 8 | SUPERNUS PHARMACEUTICALS INCCOM | 280,681 | $13.1M | 4.96% |
| 9 | ULTRAGENYX PHARMACEUTICAL INCOM | 390,879 | $13.1M | 4.96% |
| 10 | VANDA PHARMACEUTICALS INCCOM | 1,180,388 | $7.2M | 2.74% |
8 more rows. Subscribe for $29/month to see every row, download the data and use the API.